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Abstract
Primary angle closure glaucoma (PACG) is equally prevalent in Indian in Asian population as the primary open angle 
glaucoma. Eighty-six percent of people with PACG are in Asia, with approximately 48.0% in China, 23.9% in India and 
14.1% in southeast Asia. To understand PACG, it is mandatory to understand its classification and type of presentation 
with the underlying pathophysiology. The treatment options are medical, laser and/or surgical. The present article provides 
an overview of PACG.
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Glaucoma is ranked as the leading cause of irreversible blindness worldwide by the World Health Organization.[1] It has 
been estimated that 3.9 million people with glaucoma will be blind due to primary angle closure glaucoma (PACG) by 
2010. By 2020, this number is projected to increase to 5.3 million.[2] Eighty-six percent of people with PACG are in Asia, 
with approximately 48.0% in China, 23.9% in India and 14.1% in southeast Asia.[2] These numbers highlight the 
importance of understanding the disease, its natural history, and its underlying pathophysiology, so that we may try to 
establish effective methods of treatment and preventative measures to delay, or even arrest, disease progression, thereby 
reducing visual morbidity.
Patients with primary narrow angle may be classified as a primary angle closure suspect (PACS), or as having primary 
angle closure (PAC) or primary angle closure glaucoma (PACG) [Box 1].[3]
Management of patients with PAC depends on the type of clinical presentation, making the diagnosis of PACS, PAC or 
PACG, as well as correctly identifying the underlying pathophysiology. Treatment options may be medical, laser and/or 
surgical.
Medical Management
PACS: Patients assessed to be at risk of angle closure (AC) warrant prophylactic laser peripheral iridotomy. Prior to laser 
therapy, a parasympathomimetic like pilocarpine is helpful to induce pupil miosis and iris stromal thinning so that laser 
may be more easily performed. The α -agonists like brimonidine work quickly to lower IOP and may be used prior to 
and/or after laser peripheral iridotomy to prevent an IOP spike. Topical steroids instilled four times daily for a week after 
laser are beneficial in reducing post-laser intraocular inflammation.
Acute AC: Immediate medical therapy in acute AC consists of commencing IOP-lowering eye medications such as topical 
β-blocker, α -agonist and even prostaglandin analogues as soon as possible. Once the IOP is sufficiently reduced to allow 
iris reperfusion, pilocarpine is instilled to induce miosis in an attempt to widen the anterior chamber angles and reestablish 
aqueous outflow. (Pilocarpine should, however, be avoided in cases where it may exacerbate pupil block, such as in 
pseudoexfoliation, phacomorphic glaucoma and aqueous misdirection, i.e., where AC is secondary to lens-induced or retro-





lenticular mechanisms.) In addition, intravenous or oral acetazolamide 5–10 mg/kg [alternatives: hyperosmotic agents, e.g., 
intravenous 20% mannitol 1–2 g/kg, oral 50% glycerol 1–1.5 g/kg (contraindicated in diabetics), oral isosorbide 1.5–2.0 
g/kg] is often useful in helping to lower the IOP and hastening resolution of corneal edema so that a laser peripheral 
iridotomy can be definitively done. Topical steroids help to reduce intraocular inflammation, while analgesics and anti-
emetics help make the patient more comfortable, until laser peripheral iridotomy is done (see section on Lasers).
Chronic PAC/PACG: Once the patient has been treated with laser peripheral iridotomy (and laser iridoplasty where 
indicated), long-term medical treatment including topical β-blockers, α -agonists and carbonic anhydrase inhibitors can be 
used if IOP control remains suboptimal. Recent studies have demonstrated that prostaglandin analogues such as 




Laser peripheral iridotomy [Fig. 4] is the current standard approach to initial treatment of AC. It alleviates pupillary block, 
which is a common underlying mechanism of AC [Box 3]. Evidence indicates that laser peripheral iridotomy is probably 
useful in the early stages of PACG, but once extensive synechial angle closure and glaucomatous optic neuropathy have 
developed it is less likely to be effective in lowering IOP.[11] Argon and neodymium (Nd):yttrium-aluminum-garnet 
(YAG) lasers are widely used when performing laser peripheral iridotomies. A suitable combination of power and time of 
exposure appropriate to the iris thickness and degree of iris pigmentation is critical to produce the desired effect.[12] 
Nd:YAG laser is useful in helping to further enlarge the opening in the iris.[13] This method of sequential argon–Nd:YAG 
laser peripheral iridotomy is very effective, especially in thick, dark irides that are otherwise difficult to perforate with 
either one of the lasers alone. With this sequential technique, the total mean energy used has been reported to be as little as 
a third of the energy used in pure argon and Nd:YAG iridotomies.[14] The sequential technique also minimizes the 
incidence of iris bleeding.
Laser iridoplasty
Where mechanisms other than pupillary block exist, laser peripheral iridotomy may be insufficient in opening the anterior 
chamber angle. The Liwan Eye Study found residual iridotrabecular contact in 59% of Chinese eyes after successful laser 
peripheral iridotomy and attributed this to smaller anterior chamber angle dimensions and thicker irides.[16] In such cases, 
argon laser peripheral iridoplasty [Fig. 5] has been found to be effective. By applying surface photocoagulation burns in the 
iris, tissue contraction results in pulling of the peripheral iris away from the trabecular meshwork, thereby opening the 
anterior chamber angle.
Studies are ongoing to find the long-term efficacy of laser iridoplasty.
Surgical Management
Surgical management is indicated where there is inadequate control of the IOP with progression of optic nerve or visual 
field damage despite medical and laser treatment. Early lens extraction has been advocated, especially where there is a 
significant cataract that is impairing vision. If performed prior to the formation of peripheral anterior synechiae, it may 
prevent progressive AC. Other indications for early surgical management include poor compliance or intolerance to 
medical treatment and inability to cooperate with laser treatment.
Iridectomy
Since the advent of laser iridotomy, surgical peripheral iridectomy is now seldom performed. However, it may still be 
useful occasionally where the cornea fails to clear sufficiently for laser iridotomy to be performed, or in the case of a 
patient who is unable to cooperate with the laser procedure. A 2–3 mm partial-thickness incision (to about two-thirds of the 
corneal thickness) is made, usually in the superotemporal peripheral cornea. The incision may also be made at the limbus 
after a limited conjunctival peritomy. A nylon suture is placed and looped out of the incision groove. An assistant may use 
this suture to open or close the incision later so as to control the rate of aqueous egress. The anterior chamber is then 
entered with the blade held vertically. A knuckle of iris should prolapse into the wound, if necessary, with some counter-
pressure on the posterior lip of the incision. A toothed forceps is used to hold the prolapsed iris, and Vannas scissors are 
used to excise it. Neither forceps nor scissors enter the anterior chamber, thus avoiding any risk of damage to the lens or 
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other structures. The edges of the incision are then stroked to encourage the iris to retract into the anterior chamber, and the 
corneal incision is closed with one or two 10-0 nylon sutures.
Lens extraction
Removal of the lens, especially if there is any evidence of cataract, is helpful particularly where either the lens thickness or 
its anterior position is thought to be the main mechanism underlying angle closure. However, if done in the acute scenario, 
care must be taken during surgery as these eyes are usually associated with high IOPs, shallow anterior chambers, cloudy 
cornea, decreased corneal endothelial cell counts, floppy iris due to previous ischemia, posterior synechiae, bulky lens, lax 
lens zonules, and a high risk of malignant glaucoma. Reports of phacoemulsification combined with goniosynechialysis, in 
the presence of peripheral anterior synechial closure, have been encouraging.[17–19] However, there is as yet no evidence 
from good-quality randomized trials or nonrandomized studies of the effectiveness of lens extraction for chronic PACG.
[20]
Goniosynechialysis
This is usually performed in combination with lens extraction and involves mechanical stripping of peripheral anterior 
synechiae away from the trabecular meshwork, using viscoelastics or an irrigation cyclodialysis spatula.[17,18]
Trabeculectomy
Trabeculectomy in ACG is performed similarly as for open angle glaucoma, with the exception that a surgical peripheral 
iridectomy should always be performed at the time of trabeculectomy in the former. In addition, the use of antimetabolites 
should be considered. Trabeculectomy, either alone or in combination with lens extraction, should be considered after the 
acute attack of AC, if the IOP control remains suboptimal despite laser and medical treatment, especially in more advanced 
cases of ACG which are already associated with peripheral anterior synechiae, optic nerve or visual field damage. In 
acutely inflamed eyes, trabeculectomy has been reported to have low success rates.[21]
Glaucoma drainage implant
This may be considered in chronic ACG where trabeculectomy has failed to control the IOP, or in eyes that are deemed to 
be at high risk of failure with trabeculectomy.
Conclusion
Angle closure can be associated with good visual prognosis, provided it is detected early and the appropriate treatment 
given. Also, 42–72% of cases presenting with acute PAC can be satisfactorily treated with laser iridotomy alone,[22,23] 
and 60–75% of such patients recover without optic disc or visual field damage, if the IOP is promptly and adequately 
controlled.[24] However, a longer duration of the angle closure attack or a history of intermittent angle closure episodes is 
often associated with the need for additional medical or even surgical therapy.[25–27] The presence of a significant amount 
of peripheral anterior synechiae, a higher presenting IOP and a larger cup:disc ratio on presentation are other predictors of 
inadequate pressure control despite a patent laser peripheral iridotomy.[28–30] Most patients who develop a rise in IOP 
after laser peripheral iridotomy do so within the first 6 months.[27] Once glaucomatous optic neuropathy and visual field 
damage have developed, 94–100% may require further surgical treatment to control IOP.[31]
Perhaps one of the most important and cost-effective methods of managing PACG in the population currently is by 
increasing public awareness of the disease so that patients at risk, such as those with a positive family history or with ocular 
risk factors, can undergo risk assessment and prophylactic treatment where necessary. Along with this, better imaging 
devices and sound population screening strategies will go a long way to help identify others at risk and thus help to reduce 
visual morbidity due to this disease.
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Classification Based on Natural History
Primary Angle Closure Suspect: An eye in which appositional contact between the peripheral iris and posterior trabecular meshwork is present 
or considered possible, in the absence of elevated intraocular pressure (IOP), peripheral anterior synechiae (PAS), disc or Visual Field (VF) 
changes. Epidemiologically, this has been defined as an angle in which 180–270º of the posterior trabecular meshwork cannot be seen 
gonioscopically.
Primary Angle Closure: PACS with statistically raised IOP and/ or primary PAS, without disc or VF changes.
Primary Angle Closure Glaucoma: PAC with glaucomatous optic neuropathy and corresponding VF loss.
Based on objective findings, this classification is widely used in the classification of subjects in research and has been adopted in the Asia 
Pacific Glaucoma Guidelines. However, patients within each group can present differently and warrant different management. The traditional 
classification of PACG based on clinical presentation [Box 2] is more helpful to the clinician in allowing easy recognition of the type of 
management necessary.
Box 2
Classification Based on Clinical Presentation
Acute: Sudden onset of IOP elevation resulting from total angle closure, accompanied by symptoms of severe, usually unilateral, ocular pain, 
red eye, blurred vision, haloes, headache (ipsilateral frontal), nausea and vomiting.
Subacute/Intermittent/Creeping: An episode of sudden IOP elevation that is spontaneously aborted, so that symptoms are mild or even absent. 
Such subacute IOP elevations may be recurrent and therefore termed “intermittent angle closure”. Intermittent episodes can result in progressive 
PAS formation, termed “creeping angle closure”.
Chronic: Chronic IOP elevation due to the presence of PAS that permanently close the anterior chamber angle. Symptoms are usually absent.
Latent: Evidence that an open but narrow angle can and does close under certain circumstances. Asymptomatic, but PAS is often found on 
gonioscopy.
Although helpful, both forms of classifications above do not identify the pathophysiological mechanism underlying the angle closure. A 
classification devised by Ritch and colleagues[4] is useful for this purpose and should be used in parallel in order to further facilitate the clinician 
in choosing an appropriate treatment [Box 3].
Box 3
Classification Based on Anatomic Levels of Obstruction to Aqueous Flow (Pathophysiology)
Apposition of the iris to the trabecular meshwork in ACG may be due to forces acting at four anatomic levels as follows.
Iris
 Pupillary block [Fig. 1]
Non-pupil block/angle crowding mechanisms, e.g., thick peripheral iris roll [Figs. 2a, b]
 Contraction of fibrvascular membrane in neovascular glaucoma
 Contraction of fibrin in angle secondary to anterior uveitis or hyphema
 Endothelial proliferation (iridocorneoendothelial syndromes)
Epithelial downgrowth
Ciliary body
 Plateau iris configuration (forward rotation of the ciliary body (CB) or anterior position of ciliary processes) [Fig. 3]
Ciliary body cysts (pseudoplateau iris)
Lens
 Phacomorphic glaucoma (thick lens)
 Phakotopic glaucoma (anteriorly positioned lens)
Subluxed lens (e.g., pseudoexfoliation syndrome, traumatic)
Vectors posterior to lens
 Aqueous misdirection (malignant glaucoma)
 Serous or hemorrhagic choroidal detachment or effusion
 Space-occupying lesion (gas bubble, vitreous substitutes, tumor)
 Retrolenticular tissue contracture (retinopathy of prematurity, persistent hyperplastic primary vitreous)
 (Secondary causes of angle closure are shown in italics.)
 Each level of block may have a component of each of the levels preceding it, and some patients may have a combination of multiple 
mechanisms.




Anterior segment optical coherence tomography image demonstrating pupillary block mechanism
Figure 2a
Anterior segment optical coherence tomography images of the same eye taken in light
Figure 2b
Anterior segment optical coherence tomography images of the same eye taken in dark conditions demonstrating peripheral iris roll
Figure 3
Ultrasound biomicroscopy image demonstrating plateau iris configuration
Figure 4
Anterior segment photograph showing laser peripheral iridotomy in acute angle closure eye
Figure 5
Anterior segment photograph showing laser iridoplasty marks
Articles from Indian Journal of Ophthalmology are provided here courtesy of Medknow Publications
